Finance

Lists
NOT:ETR
«Նովարտիս»
146,74 €
+0,23%
(+0,34) 1D
5 նոյ, 17:35:48 GMT+1  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for NOT...
Open
146,84 €
High
147,88 €
Low
145,48 €
Mkt. cap
328,89 մլրդ
Avg. vol.
5,46 հզր
Volume
3,67 հզր
52-wk high
147,88 €
52-wk low
107,00 €
No. of employees
75 հզր
Open
146,84 €
High
147,88 €
Low
145,48 €
Mkt. cap
328,89 մլրդ
Avg. vol.
5,46 հզր
Volume
3,67 հզր
52-wk high
147,88 €
52-wk low
107,00 €
No. of employees
75 հզր
News stories
From web sources and news partners
Profile
Novartis AG is a Swiss multinational pharmaceutical corporation based in Basel, Switzerland. Novartis is one of the largest pharmaceutical companies in the world and was the eighth largest by revenue in 2024. Novartis manufactures the drugs clozapine, diclofenac, carbamazepine, valsartan, imatinib mesylate, cyclosporine, letrozole, methylphenidate, terbinafine, deferasirox, and others. Novartis was formed in 1996 by the merger of Ciba-Geigy and Sandoz. It was considered the largest corporate merger in history during that time. The pharmaceutical and agrochemical divisions of both companies formed Novartis as an independent entity. The name Novartis was based on the Latin terms, novae artes. After the merger, other Ciba-Geigy and Sandoz businesses were sold, or, like Ciba Specialty Chemicals, spun off as independent companies. The Sandoz brand disappeared for three years, but was revived in 2003 when Novartis consolidated its generic drugs businesses into a single subsidiary and named it Sandoz. Wikipedia
About «Նովարտիս»
CEOVasant Narasimhan
Employees75,3 հզր
Founded07 մրտ, 1996 թ.
HeadquartersԲասել, Basel City, Շվեյցարիա
SectorHealth Care
Industry-
Last report
27 հոկ, 2026 թ.
Fiscal period
Q3 2026
2,46 $ / 2,26 $
+8,63%beat
Revenue / Est. (USD)
15,03 մլրդ / 14,56 մլրդ
+3,25%beat
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025 թ. դեկ
2026 թ. մրտ
2026 թ. հնս
2026 թ. սեպ
Revenue
13,86 մլրդ
13,52 մլրդ
14,95 մլրդ
15,03 մլրդ
Cost of goods sold
3,54 մլրդ
3,44 մլրդ
3,68 մլրդ
3,57 մլրդ
Cost of revenue
3,54 մլրդ
3,44 մլրդ
3,68 մլրդ
3,57 մլրդ
Research and development expenses
2,84 մլրդ
2,78 մլրդ
2,74 մլրդ
2,98 մլրդ
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
3,44 մլրդ
3,14 մլրդ
3,23 մլրդ
3,08 մլրդ
Operating expense
6,46 մլրդ
5,96 մլրդ
6,10 մլրդ
6,31 մլրդ
Total operating expenses
10,00 մլրդ
9,40 մլրդ
9,78 մլրդ
9,88 մլրդ
Operating income
3,86 մլրդ
4,12 մլրդ
5,18 մլրդ
5,15 մլրդ
Other non operating income
-130,00 մլն
4,00 մլն
19,00 մլն
-14,00 մլն
EBT including unusual items
3,22 մլրդ
3,84 մլրդ
4,27 մլրդ
1,32 մլրդ
EBT excluding unusual items
3,49 մլրդ
3,78 մլրդ
4,73 մլրդ
4,66 մլրդ
Income tax expense
814,00 մլն
683,00 մլն
1,01 մլրդ
121,00 մլն
Effective tax rate
25,30%
17,79%
23,71%
9,19%
Other operating expenses
190,00 մլն
42,00 մլն
127,00 մլն
250,00 մլն
Net income
2,41 մլրդ
3,16 մլրդ
3,26 մլրդ
1,20 մլրդ
Net profit margin
17,38%
23,34%
21,83%
8,00%
Earnings per share
2,03
1,99
2,41
2,46
Interest and investment income
373,00 մլն
-
-
-
Interest expense
-304,00 մլն
-343,00 մլն
-462,00 մլն
-468,00 մլն
Net interest expenses
69,00 մլն
-343,00 մլն
-462,00 մլն
-468,00 մլն
Depreciation and amortization charges
-
-
-
-
EBITDA
4,96 մլրդ
5,24 մլրդ
6,30 մլրդ
6,38 մլրդ
Gain or loss from assets sale
80,00 մլն
-159,00 մլն
-247,00 մլն
94,00 մլն
Upcoming events
AI content may include mistakes. Learn more
Google Apps